Jane Street’s Acumen Pharmaceuticals ABOS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-18,900
Closed -$44.6K 11390
2026
Q1
$44.6K Buy
+18,900
New +$48.2K ﹤0.01% 11013
2024
Q4
Sell
-678,000
Closed -$1.68M 9266
2024
Q3
$1.68M Hold
678,000
﹤0.01% 4841
2024
Q2
$1.64M Sell
678,000
-222,200
-25% -$707K ﹤0.01% 4845
2024
Q1
$3.65M Hold
900,200
﹤0.01% 3096
2023
Q4
$3.46M Buy
+900,200
New +$2.67M ﹤0.01% 3403

Other funds holding ABOS

Jane Street's ABOS Position: Q2 2026 in Review

Jane Street sold out of Acumen Pharmaceuticals (ABOS) in Q2 2026, closing a stake of 89,661 shares — an estimated $212K sold.

Jane Street first reported a position in ABOS in Q4 2022 and held it in 13 quarters. The position peaked at $2.43M in Q1 2024. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Jane Street reported no remaining Acumen Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 89,661 Acumen Pharmaceuticals shares in Q2 2026, an estimated $212K.
  • Jane Street first reported a position in Acumen Pharmaceuticals in Q4 2022 and held it in 13 quarters.
  • Jane Street's Acumen Pharmaceuticals position peaked at $2.43M in Q1 2024.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.